Delcath Systems, Inc : DELCATH, SKY RIDGE MEDICAL CENTER INITIATE U.S. EXPANDED ACCESS PROGRAM

    Delcath Systems, Inc : DELCATH, SKY RIDGE MEDICAL CENTER INITIATE U.S.
                           EXPANDED ACCESS PROGRAM

    EAP Provides U.S. Patients Access to Second-Generation Hemofiltration
                 Cartridge Currently Under Active FDA Review

NEW YORK, Jan. 9, 2013 -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced
that Sky Ridge Medical Center in Lone  Tree, Colo., has become the first  U.S. 
center to  initiate the  Expanded  Access Program  (EAP), which  will  provide 
eligible patients  access to  treatment with  the Company's  second-generation 
hemofiltration cartridge  of  its  proprietary  chemosaturation  system.  The 
Company's New Drug  Application (NDA) is  currently under review  by the  U.S. 
Food and  Drug  Administration  (FDA)  for  the  treatment  of  patients  with 
unresectable metastatic ocular melanoma in the liver with a PDUFA goal date of
June 15, 2013.

Under certain circumstances, the  FDA allows companies  to offer early  access 
programs  to  patients  who  have  serious  or  immediately   life-threatening 
illnesses for which there are  no comparable alternative therapies. Sky  Ridge 
Medical Center,  an  American College  of  Surgeons (ACoS)  accredited  cancer 
center, is the first of several  prestigious U.S. medical centers expected  to 
offer eligible patients access to the  treatment option under the Delcath  EAP 
program.

"Patients with unresectable metastatic ocular melanoma in the liver often have
few choices  with regard  to  treatments," said  Dr.  Charles W.  Nutting,  an 
interventional radiologist with Sky  Ridge Medical Center. "Liver  involvement 
is a life-limiting factor for these  patients. We believe the expanded  access 
program  provides  patients  an  important  access  to  treatment  that  could 
potentially be beneficial."

"As an investigator  in our Phase  3 clinical  trial, Dr. Nutting  has been  a 
pioneer in the development of chemosaturation therapy, and we are pleased that
Sky Ridge Medical  Center is participating  in our EAP  under his  leadership" 
said Eamonn P.  Hobbs, President &  CEO of Delcath  Systems.  "The  EAP is  a 
beneficial program  offered by  the FDA  that provides  patients with  limited 
treatment  options  the  opportunity  to  access  drugs  that  are  still   in 
investigational stages. We felt  it was important to  pursue EAP approval  for 
our chemosaturation system with the Generation Two filter because many of  the 
patients with metastatic melanoma cannot  wait while our New Drug  Application 
is under review by the FDA."

"Dr. Nutting and his Interventional Radiology  team at Sky Ridge have led  the 
way in advancing this and other life enhancing treatments for patients,"  said 
Maureen Tarrant, CEO of  Sky Ridge Medical Center.  "As a destination  center 
for  high  quality,  compassionate  care,  we  are  proud  of  Dr.   Nutting's 
leadership, innovation and commitment to our oncology program."

About Sky Ridge Medical Center

As Douglas County, Colorado's first hospital, Sky Ridge Medical Center  opened 
on August 20, 2003 and has  since become a destination center for  healthcare, 
providing a  depth and  breadth  of quality  services and  advanced  treatment 
options to the region. Sky Ridge has earned not only quality designations from
the Joint Commission and other governing bodies but has earned high marks  for 
patient satisfaction. Sky Ridge  Medical Center is a  member of the  HealthONE 
system of excellence, which includes  seven hospitals; three surgery  centers; 
more than  30  occupational medicine/rehabilitation,  specialty  clinics;  and 
AirLife, which provides critical  care air and  ground transportation for  the 
HealthONE   system.    More   information    can    be   found    online    at 
www.skyridgemedcenter.com.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company
focused on  oncology.  Delcath's  proprietary system  for  chemosaturation  is 
designed to administer high dose chemotherapy and other therapeutic agents  to 
diseased organs  or  regions  of  the body,  while  controlling  the  systemic 
exposure of those agents. The Company's  initial focus is on the treatment  of 
primary and  metastatic liver  cancers. In  2010, Delcath  announced that  its 
randomized Phase 3 clinical trial for patients with metastatic melanoma in the
liver had  successfully  achieved the  study's  primary endpoint  of  extended 
hepatic progression-free  survival. The  Company  also completed  a  multi-arm 
Phase 2 trial to treat other liver cancers. The Company obtained authorization
to affix  a CE  Mark for  the  Generation Two  CHEMOSAT® delivery  system  for 
melphalan hydrochloride in April 2012. The right to affix the CE mark  allows 
the Company to market and sell the CHEMOSAT system for melphalan hydrochloride
in Europe. In October 2012, the  Company satisfied all of the requirements  to 
affix the  CE  Mark  to  the  Hepatic  CHEMOSAT  Delivery  System  device  for 
intra-hepatic arterial delivery and  extracorporeal filtration of  doxorubicin 
hydrochloride injection,  providing  a  regulatory pathway  for  the  CHEMOSAT 
Delivery System to deliver and filter  doxorubicin for countries in Asia  that 
accept the CE Marking as part of their national regulatory requirements.  The 
Company has not yet received FDA approval for commercial sale of its system in
the United  States.  The  Company's  NDA has  been  accepted  for  filing  and 
substantive review  by  the  FDA.  For more  information,  please  visit  the 
Company's website at www.delcath.com.

Private Securities Litigation Reform  Act of 1995 provides  a safe harbor  for 
forward-looking statements made  by the Company  or on its  behalf. This  news 
release contains  forward-looking statements,  which  are subject  to  certain 
risks and uncertainties  that can  cause actual results  to differ  materially 
from those described. Factors that may cause such differences include, but are
not  limited  to,  uncertainties  relating  to:  patient  outcomes  using  the 
chemosaturation system in the EAP, timing  of completion of the FDA's  review 
of our NDA, the extent to which the FDA may request additional information  or 
data and our ability to provide the same in a timely manner, acceptability  of 
the Phase 1,  2 and  3 clinical trial  data by  the FDA, FDA  approval of  the 
Company's NDA for the  treatment of ocular metastatic  melanoma to the  liver, 
adoption, use and resulting sales, if any, in the United States, adoption, use
and resulting sales,  if any, for  the CHEMOSAT system  to deliver and  filter 
melphalan  in  the  EEA,  our   ability  to  successfully  commercialize   the 
chemosaturation system and the  potential of the  chemosaturation system as  a 
treatment for  patients with  primary  and metastatic  disease in  the  liver, 
market acceptance of the  Gen Two CHEMOSAT system  and patient outcomes  using 
the same,  approval  of  the  current or  future  chemosaturation  system  for 
delivery and filtration  of melphalan, doxorubicin  or other  chemotherapeutic 
agents for various indications in the US and/or in foreign markets, actions by
the FDA  or other  foreign regulatory  agencies, our  ability to  successfully 
enter into  strategic partnership  and  distribution arrangements  in  foreign 
markets including Australia and  key Asian markets and  timing an revenue,  if 
any, of the same, the approval of the Hepatic CHEMOSAT Delivery System device
to deliver and filter doxorubicin in  key Asian markets and patient  outcomes 
using the same, our ability to  obtain reimbursement for the CHEMOSAT  system, 
uncertainties relating to the timing  and results of research and  development 
projects, uncertainties relating to the timing and results of future  clinical 
trials, and uncertainties regarding our ability to obtain financial and  other 
resources for  any  research, development  and  commercialization  activities. 
These factors, and others, are discussed from time to time in our filings with
the Securities and Exchange Commission. You should not place undue reliance on
these forward-looking statements,  which speak only  as of the  date they  are 
made.  We  undertake  no  obligation  to  publicly  update  or  revise   these 
forward-looking statements to reflect events  or circumstances after the  date 
they are made.

Contact Information:
Investors:                  Financial Media Consumer/Medical Media
Gregory Gin/Patty Eisenhaur Janine McCargo  Julie Johnson
EVC Group                  EVC Group       Bliss Integrated
646-445-4801/951-316-0577   646-688-0425    503-883-9103

                                     ###

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Delcath Systems, Inc via Thomson Reuters ONE
HUG#1669373
 
Press spacebar to pause and continue. Press esc to stop.